帕金森病患者起始用药分析

Analysis of Initial Pharmacotherapy in Patients with Parkinson's Disease

背景国内对新发帕金森病(PD)患者起始用药的相关研究较少。目的通过调查PD患者的起始药物选择,探讨PD患者用药现状。方法选择2015年9月—2017年4月在安徽医科大学附属安徽省立医院神经内科初次住院治疗的156例PD患者为研究对象,对性别、发病年龄、发病症状、发病至确诊时间、起始药物选择类型进行记录并比较。结果单用左旋多巴(LD)型92例,LD加多巴胺受体激动剂(DA)(LD+DA)型30例,LD加其他抗PD药物(LD+X)型3例,DA加其他抗PD药物(DA+X)型23例,非LD并非DA型8例。不同性别、发病年龄、发病症状PD患者起始药物选择情况比较,差异均无统计学意义(P>0.05)。不同发病至确诊时间PD患者起始药物选择情况比较,差异有统计学意义(P<0.05)。结论 LD是PD患者起始治疗的首选药物,DA、单胺氧化酶抑制剂及其他抗PD药物的使用率较低。

Background There are few reports regarding the initial pharmacotherapy for newly-diagnosed Parkinson＇s disease（PD） patients in China.Objective To understand the current status of pharmacotherapy for PD patients by investigating the choice of initial drugs for PD patients.Methods One hundred fifty-six patients who were initially hospitalized in Anhui Provincial Hospital Affiliated to Medical University of Anhui between September 2015 and April 2017 were selected as study subjects.Patient gender,age of disease onset,symptoms,time from disease onset to definite diagnosis,initial drugs,and drug types were collected and analyzed.Results The initial drugs chosen by the patients included the following：levodopa（LD） alone（n=92）;LD plus dopamine agonist（DA）（LD＋DA,n=30）;LD plus other anti-PD drugs（LD＋X,n=3）;DA plus other anti-PD drugs（DA＋X,n=23）;and non-LD/non-DA drugs（n=8）.Gender,age of disease onset,and disease symptoms did not affect patient choice for initial drugs（P〉0.05）,while time from disease onset to definite diagnosis did not significantly affect choice for initial drugs（P〈0.05）.Conclusion LD is a first-choice drug for most PD patients.Patients who initially use DA,monoamine oxidase inhibitors,and other anti-PD drugs are relatively fewer in number.